HIGH-THROUGHPUT ASSAYS TO IDENTIFY INHIBITORS OF CARD-CARD INTERACTIONS

识别卡-卡相互作用抑制剂的高通量检测

基本信息

  • 批准号:
    8143279
  • 负责人:
  • 金额:
    $ 23.5万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2010
  • 资助国家:
    美国
  • 起止时间:
    2010-09-15 至 2013-08-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Innate immune responses are important for initiation of homeostatic inflammatory responses to pathogens as well as sterile injury. They also initiate activation of the adaptive immune system for long term protection against pathogens. However, inflammation can itself be pathologic. In recent years a number of inflammatory syndromes have been traced to inappropriate activation of the Nod-like Receptor (NLR) branch of the innate immune system. In some instances these derive from pathogen initiated activation, in others it is sterile injury, and in yet others it is due to genetic errors in the receptors themselves. As yet there are no small molecules that inhibit NLR activation or signaling. In this proposal we describe plans to develop assays that will permit high throughput screening for inhibitors of NLR initiated signaling. NLR initiated signaling depends on interaction with downstream adaptors. Many of these interactions occur through so-called CARD domains which mediate receptor - adaptor interaction. CARD domains have been widely studied both structurally and functionally. These studies suggest that they are stable, compact, conserved structures. Conveniently, structuralstudiesshowthattheApaf1-CARD in complex with the Procaspase 9-CARD has N and C termini of both protein's chains that are accessible to solvent and in fairly close proximity, suggesting that these termini could be modified without loss of capacity to interact. In previous work we have exploited a protein fragment complementation system based on the enzyme b-lactamase (Bla). Bla can be split into two fragments which will not spontaneously recombine to form active Bla, but when these fragments are brought into proximity after being fused to two other interacting proteins, the fragments will recombine to form active Bla. In this work we propose to fuse the fragments of Bla to different, interacting CARD domains, such as the Apaf1 and Procaspase 9 CARD domains, express the two chimeric proteins in the same cell, and test for Bla function. Our preliminary results show that this does occur with Apaf1-CARD and Procaspase 9-CARD. We will then develop stable cell lines expressing the chimeras and use them to identify inhibitors of the interaction in small molecule libraries that are either commercially available or available through the NIH Molecular Library Screening Center Network. The inhibitors will be initially characterized for their ability to inhibit the CARD- CARD interactions and then for their ability to inhibit signaling initiated by the respective NLR. PUBLIC HEALTH RELEVANCE: Inflammation is a homeostatic response to infection as well as tissue injury but when it occurs inappropriately it can cause pathologic damage. This proposal describes development of a system to identify new inhibitors of inflammation that may ultimately be useful for drug development as well as basic research.
描述(由申请人提供):先天免疫反应对于启动对病原体和无菌损伤的动态平衡炎症反应是重要的。它们还启动适应性免疫系统的激活,以长期保护免受病原体侵袭。然而,炎症本身也可能是病理性的。近年来,一些炎症综合征被追溯到先天免疫系统的NOD样受体(NLR)分支的不适当激活。在一些情况下,这些是病原体启动的激活,在另一些情况下,它是无菌伤害,在另一些情况下,它是由于受体本身的遗传错误。到目前为止,还没有小分子抑制NLR的激活或信号传递。在这项提案中,我们描述了开发检测方法的计划,这些检测方法将允许高通量筛选NLR启动的信号传导抑制物。NLR发起的信令依赖于与下游适配器的相互作用。这些相互作用中的许多都是通过所谓的卡片域发生的,这些卡片域介导了受体-适配器的相互作用。卡片域在结构和功能上都得到了广泛的研究。这些研究表明,它们是稳定、紧凑、保守的结构。方便的是,结构研究表明,Apaf1-Card与Procaspase9-Card形成的复合体具有两个蛋白质链的N和C末端,这些末端可以被溶剂接触到,并且相当接近,这表明这些末端可以被修饰,而不会失去相互作用的能力。在以前的工作中,我们开发了一种基于酶B-内酰胺酶(BLA)的蛋白质片段互补系统。Bla可以分裂成两个片段,它们不会自发重组形成活性Bla,但当这些片段与另外两个相互作用的蛋白质融合后靠近时,这些片段将重新结合形成活性Bla。在这项工作中,我们建议将Bla的片段融合到不同的相互作用的卡片域,如Apaf1和Procaspase 9卡片域,在同一细胞中表达两种嵌合蛋白,并测试Bla的功能。我们的初步结果表明,Apaf1-Card和Procaspase 9-Card确实会出现这种情况。然后,我们将开发表达嵌合体的稳定细胞系,并使用它们在小分子文库中识别相互作用的抑制剂,这些小分子文库要么是商业上可用的,要么是通过NIH分子文库筛选中心网络获得的。这些抑制剂最初的特征是它们抑制卡片-卡片相互作用的能力,然后是它们抑制由各自的NLR启动的信号传递的能力。 与公共卫生相关:炎症是对感染和组织损伤的一种动态平衡反应,但当它发生不当时,可能会造成病理损害。这项建议描述了一种系统的开发,以确定新的炎症抑制剂,这些药物最终可能对药物开发和基础研究有用。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

PETER S TOBIAS其他文献

PETER S TOBIAS的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('PETER S TOBIAS', 18)}}的其他基金

Abdominal Adipose Tissue Inflammation
腹部脂肪组织炎症
  • 批准号:
    8403782
  • 财政年份:
    2012
  • 资助金额:
    $ 23.5万
  • 项目类别:
HIGH-THROUGHPUT ASSAYS TO IDENTIFY INHIBITORS OF CARD-CARD INTERACTIONS
识别卡-卡相互作用抑制剂的高通量检测
  • 批准号:
    7976276
  • 财政年份:
    2010
  • 资助金额:
    $ 23.5万
  • 项目类别:
High Throughput Screening Assays to Identify Inhibitors of TLR4 Signaling
用于鉴定 TLR4 信号传导抑制剂的高通量筛选试验
  • 批准号:
    8050426
  • 财政年份:
    2010
  • 资助金额:
    $ 23.5万
  • 项目类别:
HIGH THROUGHPUT SCREENING FOR TOLL-LIKE RECEPTORS INHIBITORS
高通量筛选 Toll 样受体抑制剂
  • 批准号:
    7437561
  • 财政年份:
    2008
  • 资助金额:
    $ 23.5万
  • 项目类别:
HIGH THROUGHPUT SCREENING FOR TOLL-LIKE RECEPTORS INHIBITORS
高通量筛选 Toll 样受体抑制剂
  • 批准号:
    7568231
  • 财政年份:
    2008
  • 资助金额:
    $ 23.5万
  • 项目类别:
HIGH THROUGHPUT SCREENING FOR TOLL-LIKE RECEPTORS INHIBITORS
高通量筛选 Toll 样受体抑制剂
  • 批准号:
    7755427
  • 财政年份:
    2008
  • 资助金额:
    $ 23.5万
  • 项目类别:
Function of microRNA in pro-inflammatory gene expression
microRNA在促炎基因表达中的功能
  • 批准号:
    8008824
  • 财政年份:
    2007
  • 资助金额:
    $ 23.5万
  • 项目类别:
High Throughput Screening for Toll-Like Receptors
Toll 样受体的高通量筛选
  • 批准号:
    7304744
  • 财政年份:
    2007
  • 资助金额:
    $ 23.5万
  • 项目类别:
TLR Signaling and Protein Fragment Complementation
TLR 信号传导和蛋白质片段互补
  • 批准号:
    6758801
  • 财政年份:
    2004
  • 资助金额:
    $ 23.5万
  • 项目类别:
DEFINING INNATE IMMUNE RECEPTOR LIGAND BINDING SITES
定义先天免疫受体配体结合位点
  • 批准号:
    7002685
  • 财政年份:
    2004
  • 资助金额:
    $ 23.5万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 23.5万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 23.5万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 23.5万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 23.5万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 23.5万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 23.5万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 23.5万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 23.5万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 23.5万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 23.5万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了